|
๐
|
Erlotinib in previously treated non-small-cell lung cancer.
19 auth.
F. Shepherd,
J. Rodrigues Pereira,
T. Ciuleanu,
E. Tan,
V. Hirsh,
S. Thongprasert,
D. Campos,
Savitree Maoleekoonpiroj,
M. Smylie,
R. Martins,
...
M. van Kooten,
M. Dediu,
B. Findlay,
D. Tu,
D. Johnston,
A. Bezjak,
G. Clark,
P. Santabarbara,
L. Seymour
|
12 |
2005 |
12
๐
|
|
๐
|
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
11 auth.
N. Thatcher,
A. Chang,
P. Parikh,
J. R. Pereira,
T. Ciuleanu,
J. Pawel,
...
S. Thongprasert,
E. Tan,
K. Pemberton,
V. Archer,
K. Carroll
|
11 |
2005 |
11
๐
|
|
๐
|
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
32 auth.
Y. Simoni,
E. Becht,
M. Fehlings,
C. Loh,
S. Koo,
K. Teng,
J. Yeong,
R. Nahar,
Tong Zhang,
H. Kared,
Kaibo Duan,
N. Ang,
M. Poidinger,
Yin Yeng Lee,
A. Larbi,
...
A. Khng,
E. Tan,
Cherylin Fu,
Ronnie Mathew,
M. Teo,
W. Lim,
C. Toh,
B. Ong,
T. Koh,
A. Hillmer,
A. Takano,
T. Lim,
E. Tan,
Weiwei Zhai,
D. Tan,
I. Tan,
E. Newell
|
10 |
2018 |
10
๐
|
|
๐
|
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
23 auth.
Keunchil Park,
E. Tan,
K. O'Byrne,
Li Zhang,
M. Boyer,
T. Mok,
V. Hirsh,
J. Yang,
K. Lee,
Shun Lu,
...
Yuankai Shi,
Sang-We Kim,
J. Laskin,
Dong-Wan Kim,
C. D. Arvis,
K. Kรถlbeck,
S. Laurie,
C. Tsai,
M. Shahidi,
Miyoung Kim,
D. Massey,
V. Zazulina,
L. Paz-Ares
|
9 |
2016 |
9
๐
|
|
๐
|
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
18 auth.
V. Miller,
V. Hirsh,
J. Cadranel,
Yuh-Min Chen,
Keunchil Park,
Sang-We Kim,
Caicun Zhou,
W. Su,
Mengzhao Wang,
Yan Sun,
...
D. Heo,
L. Crinรฒ,
E. Tan,
T. Chao,
M. Shahidi,
X. Cong,
R. Lorence,
J. Yang
|
9 |
2012 |
9
๐
|
|
๐
|
Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.
16 auth.
J. Wee,
E. Tan,
B. Tai,
H. Wong,
S. Leong,
T. Tan,
E. Chua,
E. Yang,
Khai-Mun Lee,
K. Fong,
...
H. S. Tan,
K. Lee,
S. Loong,
V. Sethi,
E. Chua,
D. Machin
|
9 |
2005 |
9
๐
|
|
๐
|
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
22 auth.
B. Solomon,
B. Besse,
T. Bauer,
E. Felip,
R. Soo,
D. Camidge,
R. Chiari,
A. Bearz,
ChiaโChi Lin,
S. Gadgeel,
...
Gregory Riely,
E. Tan,
T. Seto,
L. James,
J. Clancy,
A. Abbattista,
J. Martini,
Joseph Chen,
G. Peltz,
H. Thurm,
S. Ou,
A. Shaw
|
9 |
2018 |
9
๐
|
|
๐
|
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
55 auth.
K. Ng,
A. Hillmer,
C. Chuah,
W. Juan,
T. Ko,
Audrey S. M. Teo,
P. Ariyaratne,
N. Takahashi,
K. Sawada,
Yao Fei,
S. Soh,
W. Lee,
J. Huang,
J. Allen,
X. Woo,
...
N. Nagarajan,
Vikrant Kumar,
A. Thalamuthu,
W. Poh,
Ai Leen Ang,
H. Mya,
G. How,
L. Y. Yang,
L. Koh,
B. Chowbay,
C. Chang,
V. Nadarajan,
W. Chng,
H. Than,
L. Lim,
Y. Goh,
Shenli Zhang,
Dianne Poh,
Patrick Tan,
J. Seet,
M. Ang,
N. Chau,
Q. Ng,
D. Tan,
M. Soda,
K. Isobe,
M. Nรถthen,
T. Wong,
Atif Shahab,
Xiaoan Ruan,
Valรจre Cacheux-Rataboul,
W. Sung,
E. Tan,
Y. Yatabe,
H. Mano,
R. Soo,
T. Chin,
W. Lim,
Y. Ruan,
S. Ong
|
9 |
2012 |
9
๐
|
|
๐
|
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
17 auth.
C. Lee,
Chris Brown,
R. Gralla,
V. Hirsh,
S. Thongprasert,
C. Tsai,
E. Tan,
J. Ho,
D. Chu,
Adel M Zaatar,
...
Jemela Anne Osorio Sanchez,
V. Vu,
J. Au,
A. Inoue,
S. Lee,
V. Gebski,
J. Yang
|
9 |
2013 |
9
๐
|
|
๐ข
|
Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.
11 auth.
C. Toh,
F. Gao,
W. Lim,
S. Leong,
K. Fong,
S. Yap,
...
A. Hsu,
P. Eng,
H. Koong,
A. Thirugnanam,
E. Tan
|
8 |
2006 |
8
๐ข
|
|
๐
|
Human Innate Lymphoid Cell Subsets Possess TissueโType Based Heterogeneity in Phenotype and Frequency
31 auth.
Y. Simoni,
M. Fehlings,
H. Klรธverpris,
N. McGovern,
S. Koo,
C. Loh,
Shawn Lim,
A. Kurioka,
J. Fergusson,
C. Tang,
M. Kam,
Koh Dennis,
T. Lim,
A. C. Fui,
Chan Weng Hoong,
...
J. Chan,
M. A. Curotto de Lafaille,
Sriram Narayanan,
S. Baig,
M. Shabeer,
S. Toh,
Henry Kun Kiaang Tan,
Rosslyn Anicete,
E. Tan,
A. Takano,
P. Klenerman,
A. Leslie,
D. Tan,
I. Tan,
F. Ginhoux,
E. Newell
|
8 |
2017 |
8
๐
|
|
๐
|
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
20 auth.
L. Paz-Ares,
E. Tan,
K. O'Byrne,
L. Zhang,
V. Hirsh,
M. Boyer,
J.C. Yang,
T. Mok,
K. Lee,
S. Lu,
...
Y. Shi,
D. Lee,
J. Laskin,
D-W. Kim,
S. Laurie,
K. Kรถlbeck,
J. Fan,
N. Dodd,
A. Maฬrten,
K. Park
|
8 |
2016 |
8
๐
|
|
๐
|
Genomic landscape of lung adenocarcinoma in East Asians
43 auth.
Jianbin Chen,
Hechuan Yang,
A. Teo,
Lidyana Bte Amer,
F. G. Sherbaf,
C. Tan,
J. Alvarez,
Bingxin Lu,
Jia Qi Lim,
A. Takano,
R. Nahar,
Yin Yeng Lee,
C. Phua,
K. P. Chua,
L. Suteja,
...
P. Chen,
M. Chang,
T. Koh,
B. Ong,
D. Anantham,
A. Hsu,
A. Gogna,
C. W. Too,
Z. Aung,
Y. Lee,
Lanying Wang,
T. Lim,
A. Wilm,
P. S. Choi,
Poh Yong Ng,
C. Toh,
W. Lim,
Siming Ma,
B. Lim,
Jin Liu,
W. Tam,
A. Skanderup,
J. Yeong,
E. Tan,
C. Creasy,
D. Tan,
A. Hillmer,
W. Zhai
|
8 |
2020 |
8
๐
|
